ArticleContemporary clinical trials communications2025

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials.

Luigi Taranto-Montemurro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.